178 related articles for article (PubMed ID: 15343346)
1. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome.
Lightfoot J; Hitzler JK; Zipursky A; Albert M; Macgregor PF
Leukemia; 2004 Oct; 18(10):1617-23. PubMed ID: 15343346
[TBL] [Abstract][Full Text] [Related]
2. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
3. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
[TBL] [Abstract][Full Text] [Related]
4. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.
Kobayashi K; Usami I; Kubota M; Nishio T; Kakazu N
Cancer Genet Cytogenet; 2005 Apr; 158(2):184-7. PubMed ID: 15796967
[TBL] [Abstract][Full Text] [Related]
6. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
7. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
8. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang HY; Chen W
Cytometry B Clin Cytom; 2015; 88(4):244-52. PubMed ID: 25361478
[TBL] [Abstract][Full Text] [Related]
9. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
[TBL] [Abstract][Full Text] [Related]
10. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
11. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
12. Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome.
Holt SE; Brown EJ; Zipursky A
J Pediatr Hematol Oncol; 2002 Jan; 24(1):14-7. PubMed ID: 11902731
[TBL] [Abstract][Full Text] [Related]
13. Leukemia in Down syndrome: a review.
Zipursky A; Poon A; Doyle J
Pediatr Hematol Oncol; 1992; 9(2):139-49. PubMed ID: 1388043
[TBL] [Abstract][Full Text] [Related]
14. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
[TBL] [Abstract][Full Text] [Related]
15. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
17. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
18. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
[TBL] [Abstract][Full Text] [Related]
19. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
20. Origins of leukaemia in children with Down syndrome.
Hitzler JK; Zipursky A
Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
